curb glp 1 Modere | Burn, Curb, Sculpt | Modere Obesity drugs regulate neural systems

Description

Funding This work was supported by Statutory Funds of the Laboratory of Immunoendocrinology, Maj Institute of Pharmacology, Cracow, Poland

Therapeutic Advan Endocrinology Metabolism

Canada Europe Germany France UK Italy Spain Netherlands Russia Rest of Europe Asia Pacific China Japan India Malaysia South Korea Indonesia Australia Vietnam Rest of Asia Pacific Middle East & Africa Saudi Arabia UAE Israel South Africa Rest of Middle East & Africa Latin America Mexico Brazil Argentina Rest of Latin America GLP-1 Market Report Scope Source: Polaris Market Research Analysis FAQ's The GLP-1 market was valued at USD 52.82 billion in 2025 and is projected to reach USD 133.92 billion by 2034

Glucose-dependent insulinotropic polypeptide (GIP) Combining GLP-1 with its incretin partner GIP is a promising strategy (Figure 2) under investigation for treating T2D and obesity